Last reviewed · How we verify
"MAX-40279-01" and "Toripalimab"
Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Nasopharyngeal carcinoma, Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | "MAX-40279-01" and "Toripalimab" |
|---|---|
| Sponsor | Maxinovel Pty., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Toripalimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade releases the brake on anti-tumor immunity, restoring T cell activation, proliferation, and cytotoxic function against malignant cells. The drug is used in various solid tumors where PD-L1 expression correlates with response.
Approved indications
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Melanoma
- Esophageal squamous cell carcinoma
Common side effects
- Fatigue
- Decreased appetite
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "MAX-40279-01" and "Toripalimab" CI brief — competitive landscape report
- "MAX-40279-01" and "Toripalimab" updates RSS · CI watch RSS
- Maxinovel Pty., Ltd. portfolio CI